Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Senti Biosciences
Biotech
Private equity firms take over bluebird's nest—Chutes & Ladders
Private equity firms take over bluebird’s nest. Novartis vet vaults to FoRx. Indivior IDs next CEO.
Darren Incorvaia
,
Zoey Becker
Feb 28, 2025 8:30am
Senti, Celest take cell therapy to China in $156M deal
Nov 7, 2023 10:15am
Senti slams brakes on CAR-NK program to eke out remaining cash
Jan 27, 2023 9:40am
Alchemab CEO resigns citing 'personal reasons'—Chutes & Ladders
May 27, 2022 9:30am
Senti shows its CAR-NK cells are more than just a gene circuit
Apr 8, 2022 1:00pm
Senti to go public in $296M SPAC deal before hitting the clinic
Dec 20, 2021 3:55pm
